Sidney A. Spector
Corporate Officer/Principal chez University of Arizona College of Medicine
Profil
Sidney A.
Spector is currently an Associate Professor at the University of Arizona College of Medicine and the Chief Medical Officer at Proxenia Venture Partners LLC.
Previously, he held positions as the Vice President of US Medical Affairs at Novartis Gene Therapies, Inc., the Vice President at AveXis EU Ltd., and the Senior VP of Global Strategy & Medical Affairs at Brainstorm Cell Therapeutics, Inc. Dr. Spector obtained his doctorate degree from the University of California, Los Angeles and the Sackler School of Medicine.
Postes actifs de Sidney A. Spector
| Sociétés | Poste | Début |
|---|---|---|
| University of Arizona College of Medicine | Corporate Officer/Principal | - |
Proxenia Venture Partners LLC
 Proxenia Venture Partners LLC Investment ManagersFinance Proxenia Venture Partners LLC (Proxenia Venture Partners) is a venture capital firm founded in 2016 by Menghis Bairu. The firm is headquartered in wilmington, Delaware. | Corporate Officer/Principal | - |
Anciens postes connus de Sidney A. Spector
| Sociétés | Poste | Fin |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/03/2023 |
AveXis EU Ltd.
 AveXis EU Ltd. BiotechnologyHealth Technology Part of Novartis AG, AveXis EU Ltd. develops gene therapy products. The company is based in Dublin, Ireland. | Private Equity Investor | 01/06/2019 |
| AVEXIS INC | Corporate Officer/Principal | - |
Formation de Sidney A. Spector
| University of California, Los Angeles | Doctorate Degree |
| Sackler School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
AveXis EU Ltd.
AveXis EU Ltd. BiotechnologyHealth Technology Part of Novartis AG, AveXis EU Ltd. develops gene therapy products. The company is based in Dublin, Ireland. | Health Technology |
Proxenia Venture Partners LLC
Proxenia Venture Partners LLC Investment ManagersFinance Proxenia Venture Partners LLC (Proxenia Venture Partners) is a venture capital firm founded in 2016 by Menghis Bairu. The firm is headquartered in wilmington, Delaware. | Finance |
